share_log

Cantor Fitzgerald Initiates Coverage On Novo Nordisk With Overweight Rating, Announces Price Target of $120

Cantor Fitzgerald Initiates Coverage On Novo Nordisk With Overweight Rating, Announces Price Target of $120

坎託·菲茨傑拉德以增持評級啓動對諾和諾德的報道,宣佈目標股價爲120美元
Benzinga ·  2023/12/01 08:49

Cantor Fitzgerald analyst Louise Chen initiates coverage on Novo Nordisk (NYSE:NVO) with a Overweight rating and announces Price Target of $120.

坎託·菲茨傑拉德分析師路易絲·陳以增持評級開始對諾和諾德(紐約證券交易所代碼:NVO)進行報道,並宣佈目標股價爲120美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論